Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 8;20(1):9.
doi: 10.1186/s12914-020-00229-9.

Misoprostol for the prevention of post-partum haemorrhage in Mozambique: an analysis of the interface between human rights, maternal health and development

Affiliations

Misoprostol for the prevention of post-partum haemorrhage in Mozambique: an analysis of the interface between human rights, maternal health and development

Karen Hobday et al. BMC Int Health Hum Rights. .

Abstract

Background: Mozambique has high maternal mortality which is compounded by limited human resources for health, weak access to health services, and poor development indicators. In 2011, the Mozambique Ministry of Health (MoH) approved the distribution of misoprostol for the prevention of post-partum haemorrhage (PPH) at home births where oxytocin is not available. Misoprostol can be administered by a traditional birth attendant or self-administered. The objective of this paper is to examine, through applying a human rights lens, the broader contextual, policy and institutional issues that have influenced and impacted the early implementation of misoprostol for the prevention of PPH. We explore the utility of rights-based framework to inform this particular program, with implications for sexual and reproductive health programs more broadly.

Methods: A human rights, health and development framework was used to analyse the early expansion phase of the scale-up of Mozambique's misoprostol program in two provinces. A policy document review was undertaken to contextualize the human rights, health and development setting in Mozambique. Qualitative primary data from a program evaluation of misoprostol for the prevention of PPH was then analysed using a human rights lens; these results are presented alongside three examples where rights are constrained.

Results: Structural and institutional challenges exacerbated gaps in the misoprostol program, and sexual and reproductive health more generally. While enshrined in the constitution and within health policy documents, human rights were not fully met and many individuals in the study were unaware of their rights. Lack of information about the purpose of misoprostol and how to access the medication contributed to power imbalances between the state, health care workers and beneficiaries. The accessibility of misoprostol was further limited due to dynamics of power and control.

Conclusions: Applying a rights-based approach to the Mozambican misoprostol program is helpful in contextualising and informing the practical changes needed to improve access to misoprostol as an essential medicine, and in turn, preventing PPH. This study adds to the evidence of the interconnection between human rights, health and development and the importance of integrating the concepts to ensure women's rights are prioritized within health service delivery.

Keywords: Development; Human rights; Maternal health; Mozambique; Post-partum haemorrhage; Right to health.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The Health, Human Rights and Development Triangle (Originally printed in Tarantola et al., 2008 [20] with permission obtained to re-print. This figure has been republished in Tarantola et al., 2013 [21])
Fig. 2
Fig. 2
The Evolution of the Distribution of Misoprostol for Prevention of Postpartum Hemorrhage in Mozambique (Figure developed by K. Hobday and was published in Hobday et al., 2019 [22] which is an open access journal)

References

    1. World Health Organization. Maternal mortality: Key facts Geneva. Switzerland2018 [Available from: http://www.who.int/en/news-room/fact-sheets/detail/maternal-mortality. Accessed 2 May 2018.
    1. World Health Organization . WHO recommendations for the prevention and treatment of postpartum haemorrhage. Italy: WHO; 2012. pp. 1–41. - PubMed
    1. World Health Organization . WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Geneva: WHO; 2018. - PubMed
    1. Raghavan S, Abbas D, Winikoff B. Misoprostol for prevention and treatment of postpartum hemorrhage: what do we know? What is next? Int J Gynaecol Obstet. 2012;119(Suppl 1):S35–S38. doi: 10.1016/j.ijgo.2012.03.013. - DOI - PubMed
    1. Prata N, Passano P, Bell S, Rowen T, Potts M. New hope: community-based misoprostol use to prevent postpartum haemorrhage. Health Policy Plan. 2013;28(4):339–346. doi: 10.1093/heapol/czs068. - DOI - PubMed

Publication types